v3.24.1
Earnings Per Common Share
 9 Months Ended
Jan. 31, 2024
Earnings Per Share [Abstract]  
Earnings Per Common Share

Note 4 – Earnings Per Common Share

 

Net income per common and diluted share were calculated as follows for the three- and nine-month periods ended January 31, 2024 and 2023:

 

   Three Months
Ended
January 31, 2024		   Three Months
Ended
January 31, 2023		   Nine Months
Ended
January 31, 2024		   Nine Months
Ended
January 31, 2023		 
Net income (loss) attributable to common stockholders – basic  $(2,227,542)  $1,696,499   $(2,379,581)  $1,944,114 
Adjustments to net income   —    —    —    — 
Net income (loss) attributable to common stockholders – diluted  $(2,227,542)  $1,696,499   $(2,379,581)  $1,944,144 
                     
Weighted average common shares outstanding - basic   11,466,523    5,166,299    9,457,740    4,208,216 
Effect of dilutive securities   —    250    —    250 
Weighted average common shares outstanding – diluted   11,466,523    5,166,549    9,457,740    4,208,466 
                     
Earnings (loss) per common share - basic  $(0.19)  $0.33   $(0.25)  $0.46 
Earnings (loss) per common share - diluted  $(0.19)  $0.33   $(0.25)  $0.46 

 

250 shares of common stock that are issuable pursuant to a stock subscription agreement are included in the calculation of diluted earnings per share for the three and nine months ended January 31, 2023. The 250 shares are not included in the calculation of diluted earnings per share for the three and nine months ended January 31, 2024 because their effect is anti-dilutive.

 

Outstanding vested warrants to purchase 11,110,932 and 1,541,682 shares of common stock are not included in the calculation of earnings per share for the three and nine months ended January 31, 2024 and 2023, respectively, because their effect is anti-dilutive.

 

Outstanding vested options to purchase 635,146 and 169,333 shares of common stock are not included in the calculation of earnings per share for the three and nine months ended January 31, 2024 and 2023, respectively, because their effect is anti-dilutive.